Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT01969565Phase 2Terminated
- Sponsor
- Emory University
- Start
- Aug 2013
- Primary completion
- Oct 2014
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by Emory University. Primary endpoints: Tolerability and Safety of Increasing Doses of Carfilzomib in Combination With Dexamethasone at 24 months and Patients With >= VGPR (Very Good Partial Response) at 8 months. Started Aug 2013; status: terminated.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01969565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01969565.